POTENTIAL BIOCHEMICAL DIAGNOSTIC FOR ALZHEIMERS DISEASE

阿尔茨海默病的潜在生化诊断

• 批准号: 3487705
• 负责人: BARBARA L CORDELL
• 金额: $ 5万
• 依托单位: CALIFORNIA BIOTECHNOLOGY, INC.
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-05-01 至 1988-10-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3487705
• 关键词: Alzheimer's disease; RNA; amyloid proteins; antibody; brain disorder diagnosis; complementary DNA; diagnosis design /evaluation; fibroblasts; gene expression; genetic manipulation; human tissue; immunologic assay /test; laboratory mouse; laboratory rabbit; leukocytes; molecular cloning; monoclonal antibody; nucleic acid probes; nucleic acid sequence; synthetic peptide

Alzheimer's disease is a growing medical problem afflicting 5% of the over-65 population in the US. Despite its prevalence, neither positive diagnoses nor efficacious treatments exist. Definitive diagnosis is made on autopsy using the histopathological hallmarks of the disease - fibrillar amyloid protein which is deposited extracellularly as plaque cores and as cerebrovasculature amyloid. These structures occur at approximately 1000-fol greater frequency than in a normal aged brain. The major core protein of amyloid fibrils has been purified and recently the cDNA cloned. The aim of phase I is to develop nucleic acid and antibody reagents to the core protein which can be utilized to build a biochemica diagnostic for Alzheimer's disease. Using the cDNA sequence, core protein-specific antibodies will be generated either from synthetic peptides or from proteins expressed by recombinant methods. In phase II sera will be screened with the antibodies and the nucleic acid probes to assess qualitative and/or quantitative differences reflecting the disease state. Such differences would then be developed into a positive diagnostic for Alzheimer's disease.

阿尔茨海默病是一个日益严重的医疗问题， 美国65岁以上的人口。 尽管它很流行， 既没有明确的诊断也没有有效的治疗。 明确 诊断是在尸检中使用组织病理学特征 纤维状淀粉样蛋白 在细胞外作为斑块核心和血管淀粉样蛋白。 这些结构发生在大约1000-fol以上 比正常老年人的大脑频率要高。 主要的核心蛋白 淀粉样蛋白原纤维已被纯化，最近cDNA已被克隆。 第一阶段的目标是开发核酸和抗体 核心蛋白的试剂，其可用于构建 阿尔茨海默病的生化诊断。 使用cDNA 序列，将产生核心蛋白特异性抗体 或者来自合成肽或者来自由 重组方法。 在II期，将使用 抗体和核酸探针来评估定性和/或 反映疾病状态的数量差异。 等 然后，差异将发展成为一个积极的诊断， 老年痴呆症